Table 1 Baseline clinical characteristics of the patients
| Â | Before IPTW | After IPTW | ||||
|---|---|---|---|---|---|---|
Characteristics | SGLT2i group | DPP-4i group | p-value | SGLT2i group | DPP-4i group | p-value |
(n = 186) | (n = 593) | (n = 537) | (n = 532) | |||
Male patients | 150 (80.7) | 422 (71.2) | 0.011 | 358 (66.7) | 388 (72.9) | 0.364 |
Age, years | 59.11 ± 11.52 | 66.12 ± 10.86 | < 0.001 | 63.21 ± 11.17 | 63.74 ± 11.33 | 0.694 |
Age ≥ 75 years | 20 (10.7) | 153 (25.8) | < 0.001 | 76 (14.2) | 105 (19.8) | 0.269 |
EMS utilization | 45 (24.2) | 122 (20.6) | 0.294 | 109 (20.2) | 105 (19.7) | 0.914 |
BMI ≥ 25 kg/m2 | 76 (43.4) | 221 (40.0) | 0.426 | 212 (39.4) | 215 (40.4) | 0.880 |
Killip class III-IV | 17 (9.1) | 51 (8.6) | 0.830 | 52 (9.7) | 55 (10.3) | 0.877 |
Previous history | Â | Â | Â | Â | Â | Â |
Hypertension | 113 (60.8) | 395 (66.7) | 0.136 | 350 (65.1) | 344 (64.6) | 0.935 |
DM | 186 (100.0) | 593 (100.0) | NA | 537 (100.0) | 532 (100.0) | NA |
Dyslipidemia | 48 (25.8) | 134 (22.6) | 0.367 | 125 (23.3) | 133 (25.0) | 0.741 |
Prior CAD | 19 (10.2) | 116 (19.6) | 0.003 | 46 (8.6) | 72 (13.5) | 0.176 |
Prior heart failure | 6 (3.2) | 9 (1.5) | 0.140 | 10 (1.8) | 9 (1.8) | 0.970 |
Prior CVA | 12 (6.5) | 56 (9.5) | 0.214 | 33 (6.1) | 49 (9.2) | 0.310 |
DM duration | Â | Â | 0.078 | Â | Â | Â |
0 to 10 years | 98 (73.7) | 259 (65.4) | Â | NA | NA | NA |
> 10 years | 35 (26.3) | 137 (34.6) |  | NA | NA | NA |
Smoking | 110 (61.1) | 278 (48.7) | 0.004 | 254 (47.2) | 283 (53.2) | 0.350 |
Family history of CAD | 16 (8.9) | 44 (7.6) | 0.580 | 40 (7.5) | 42 (7.9) | 0.885 |
Use of thrombolysis | 2 (1.1) | 2 (0.3) | 0.243 | 3 (0.5) | 2 (0.4) | 0.811 |
LVEF, % | 51.07 ± 12.20 | 52.58 ± 11.40 | 0.126 | 53.04 ± 12.55 | 52.00 ± 11.57 | 0.502 |
LVEF < 40% | 29 (15.8) | 70 (12.2) | 0.205 | 79 (14.7) | 78 (14.7) | 0.984 |
STEMI diagnosis | 100 (53.8) | 227 (38.3) | < 0.001 | 244 (45.5) | 241 (45.3) | 0.976 |
HbA1c, % | 8.33 ± 1.87 | 7.70 ± 1.53 | < 0.001 | 7.88 ± 1.65 | 7.85 ± 1.62 | 0.886 |
Discharge medications | Â | Â | Â | Â | Â | Â |
Aspirin | 185 (99.5) | 593 (100.0) | 0.239 | 156 (99.7) | 532 (100.0) | 0.327 |
P2Y12 inhibitor | 186 (100.0) | 586 (98.8) | 0.207 | 537 (100.0) | 532 (100.0) | NA |
Beta-blocker | 163 (87.6) | 455 (76.7) | 0.001 | 431 (80.2) | 416 (78.3) | 0.734 |
ACE inhibitor or ARB | 142 (76.3) | 461 (77.7) | 0.691 | 444 (82.5) | 427 (80.3) | 0.603 |
Statin | 182 (97.9) | 564 (95.1) | 0.143 | 520 (96.7) | 516 (97.0) | 0.901 |
Ezetimibe | 23 (12.4) | 67 (11.3) | 0.691 | 56 (10.5) | 62 (11.6) | 0.786 |